Oximio Ukraine is represented at CTS Executive Board at EBA
We are delighted to announce that Oximio Ukraine is represented at the Clinical Trials Subcommittee (CTS) Executive Board at the European Business Association (EBA).
Established in 1999, the EBA provides a forum in which members can discuss and find solutions to common problems affecting business in Ukraine. This initiative was initially supported by the European Commission and has grown to become one of the largest and most influential business communities in the country.
There are many subcommittees of the EBA and one of these is the Clinical Trial Services (CTS) subcommittee. The CTS is focused on the conduct of clinical trials in Ukraine and furthermore the harmonisation of the regulatory groups by cooperating with the state health authorities.
Given the importance of various logistical challenges during the war in Ukraine, the CTS Board decided to include an additional member of the Board, a representative of a CTS logistics company. This CTS board member shall discuss and oversee the difficulties of the provision of logistics.
As a result of the voting, Olga Vizgalova, Oximio MD Ukraine, has been chosen as the additional member of the CTS subcommittee Board with a focus on logistics.
Mykola Nikolaiev, CEO of Oximio commented, “This accomplishment demonstrates the recognition and importance of Oximio by the EBA. This is a great achievement to represent Ukraine and to help the EBA to understand the challenges faced in the clinical trials and health care communities”.